HomeREGULATORY
REGULATORY

Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
(Apr.11.2018)

A key health ministry reimbursement panel on April 11 gave the nod to NHI prices for a batch of new drugs for their listing on April 18, including big names like Dupixent (dupilumab), Tecentriq (atezolizumab), and Lynparza (olaparib). Meanwhile, Parmodia (pemafibrate), Kowa’s hyperlipidemia hopeful, will skip listing yet again as its price talks with regulators apparently ended in a rupture ...
(LOG IN FOR FULL STORY)